Southpoint Capital Advisors LP Fennec Pharmaceuticals Inc. Transaction History
Southpoint Capital Advisors LP
- $3.46 Billion
- Q3 2025
A detailed history of Southpoint Capital Advisors LP transactions in Fennec Pharmaceuticals Inc. stock. As of the latest transaction made, Southpoint Capital Advisors LP holds 4,077,214 shares of FENC stock, worth $33 Million. This represents 1.08% of its overall portfolio holdings.
Number of Shares
4,077,214
Previous 4,077,214
-0.0%
Holding current value
$33 Million
Previous $33.8 Million
10.85%
% of portfolio
1.08%
Previous 0.98%
Shares
2 transactions
Others Institutions Holding FENC
# of Institutions
87Shares Held
14.2MCall Options Held
10KPut Options Held
83.8K-
Sonic Gp LLC Honolulu, HI2.41MShares$19.5 Million33.54% of portfolio
-
Solas Capital Management, LLC Darien, CT2.19MShares$17.7 Million14.46% of portfolio
-
Black Rock Inc. New York, NY1.19MShares$9.62 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA956KShares$7.74 Million0.0% of portfolio
-
Aigh Capital Management LLC Baltimore, MD682KShares$5.52 Million1.04% of portfolio
About FENNEC PHARMACEUTICALS INC.
- Ticker FENC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,067,300
- Market Cap $211M
- Description
- Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...